Diagnostic accuracy of fibroblast growth factor 23 for predicting acute kidney injury in patients with acute decompensated heart failure

AbstractBackgroundElevated plasma levels of fibroblast growth factor 23 (FGF23) have emerged as a predictor for the development of acute kidney injury (AKI) in patients undergoing cardiac surgery and those with critical illnesses. However, accurate data in cases involving acute decompensated heart failure (ADHF) remains limited.MethodsSingle centre cohort study was performed in patients admitted for ADHF. Plasma c‐terminal FGF23 (c‐FGF23) was measured at baseline and 24 hours after being diagnosed with ADHF. AKI was defined by KDIGO 2012 criteria.ResultsThe study enrolled 62 patients diagnosed with ADHF. The incidence of AKI was 45% and significantly increased the risk of death. Patients developing AKI had significantly higher levels of plasma c‐FGF23 at baseline in comparison with those not developing AKI [median value 1258.5 (57.2, 15 850) vs 230.2 (68.515 850) RU/mL, P = .005]. During the first 24 hours, plasma c‐FGF23 levels decreased in both groups, and the levels of c‐FGF23 at 24 hours were consistent with the baseline [861.8 (75.7, 15 850) vs 226.3 (56, 5450.8) RU/mL, P = .006]. Receiver operating characteristic analysis of both first time and second time for plasma c‐FGF23 collection yielded an area under curve of 0.71 for the prediction of AKI incidence. With the cut‐off point at 450 RU/mL, the sensitivity and specificity of plasma c‐FGF23 at the baseline for predicting AKI were 71.4% and 61.8% respectively.ConclusionPlasma c‐FGF23 may serve as a novel biomarker for development of AKI in patients with ADHF. These results should be revalidated in larger‐scale, cohort studies.